StockData

Brainsway vs DarioHealth

BWAY and DRIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BWAY and DRIO compare

Brainsway grew revenue faster over the last twelve months (27.3% versus −22.6% for DarioHealth).

DarioHealth scores higher on the StockData Score (8 against 5 for Brainsway), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBWAYDRIO
Size and price
Market cap–$11.3M
Share price$9.39$1.15
Change, 1 year17.3%−88.4%
Change, 5 years156%−99.6%
Beta (5Y)1.65−0.03
Employees129160
StockData Score
Total score58 (better)
Valuation score04 (better)
Growth score4 (better)2
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/E–0.3×
P/S–0.5×
P/B–0.2×
PEG–0.01
FCF yield–−226%
Fair value–$92.75
Margin of safety–98.8%
Growth
Revenue growth (TTM)27.3% (better)−22.6%
Revenue growth, 5Y average18.8%24.2% (better)
EPS growth (TTM)260%–
EPS growth, 5Y average–20.3%
Profitability
Gross margin75.4% (better)58.2%
Operating margin8.3% (better)−152%
Net margin–−170%
FCF margin–−121%
Return on equity–−59.9%
Return on invested capital–−34.8%
Financial health
Debt / equity–0.56
Interest coverage2.0× (better)−7.0×
Current ratio3.59 (better)2.31
Altman Z-score–−7.34
Piotroski F-score–4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions29.2%15.0%
Held by insiders25.5%13.7%
Insider net buying, 12 months–$100K
Short interest, % of float–1.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.